bimatoprost 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prostaglandins 371 155206-00-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lumigan
  • bimatoprost
  • prostamide
A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
  • Molecular weight: 415.57
  • Formula: C25H37NO4
  • CLOGP: 1.75
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 89.79
  • ALOGS: -4.35
  • ROTB: 12

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.80 mg/mL Benet LZ, Broccatelli F, Oprea TI
Vd (Volume of distribution) 0.67 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 25 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.12 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.45 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 8, 2002 EMA
March 16, 2001 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 2251.98 17.13 614 14212 19678 50570620
Eye irritation 1786.04 17.13 494 14332 16646 50573652
Erythema of eyelid 1735.23 17.13 321 14505 1512 50588786
Madarosis 1664.75 17.13 327 14499 2233 50588065
Eye pruritus 1419.50 17.13 386 14440 12148 50578150
Eyelids pruritus 985.76 17.13 175 14651 617 50589681
Eyelid irritation 725.20 17.13 121 14705 260 50590038
Eye swelling 583.50 17.13 220 14606 19924 50570374
Eyelid oedema 549.96 17.13 174 14652 9292 50581006
Treatment failure 480.77 17.13 364 14462 137273 50453025
Eye pain 345.79 17.13 168 14658 28281 50562017
Intraocular pressure increased 310.34 17.13 99 14727 5417 50584881
Blepharal pigmentation 278.31 17.13 42 14784 28 50590270
Trichorrhexis 236.90 17.13 57 14769 1073 50589225
Eye discharge 216.13 17.13 74 14752 5049 50585249
Dry eye 216.09 17.13 128 14698 31967 50558331
Skin hyperpigmentation 214.00 17.13 74 14752 5202 50585096
Drug ineffective 183.94 17.13 589 14237 818744 49771554
Lacrimation increased 181.57 17.13 92 14734 16900 50573398
Vision blurred 179.61 17.13 163 14663 78484 50511814
Eyelid pain 179.01 17.13 35 14791 230 50590068
Scleral hyperaemia 154.44 17.13 31 14795 237 50590061
Growth of eyelashes 152.65 17.13 29 14797 160 50590138
Blepharitis 151.14 17.13 46 14780 2149 50588149
Inappropriate schedule of product administration 146.82 17.13 140 14686 71691 50518607
Eyelid exfoliation 142.57 17.13 26 14800 110 50590188
Eyelash discolouration 126.08 17.13 20 14806 26 50590272
Wrong technique in product usage process 120.69 17.13 112 14714 55398 50534900
Iris hyperpigmentation 116.94 17.13 17 14809 5 50590293
Hypersensitivity 107.70 17.13 211 14615 214950 50375348
Product administered at inappropriate site 105.80 17.13 36 14790 2407 50587891
Foreign body sensation in eyes 103.87 17.13 33 14793 1778 50588520
Swelling of eyelid 90.82 17.13 30 14796 1830 50588468
Corneal endothelial cell loss 90.07 17.13 13 14813 3 50590295
Eyelid thickening 89.69 17.13 16 14810 58 50590240
Erythema 83.60 17.13 152 14674 146262 50444036
Visual acuity reduced 82.85 17.13 59 14767 20080 50570218
Abnormal sensation in eye 74.40 17.13 25 14801 1608 50588690
Eyelid rash 73.88 17.13 14 14812 76 50590222
Eye colour change 69.77 17.13 16 14810 242 50590056
Ocular discomfort 66.65 17.13 28 14798 3345 50586953
Eyelid margin crusting 66.53 17.13 19 14807 709 50589589
Skin irritation 65.90 17.13 36 14790 7691 50582607
Hair growth abnormal 59.94 17.13 24 14802 2537 50587761
Eyelid skin dryness 56.97 17.13 11 14815 67 50590231
Skin discolouration 56.02 17.13 58 14768 32699 50557599
Eyelid disorder 51.78 17.13 18 14808 1283 50589015
Incorrect dose administered 51.30 17.13 67 14759 48347 50541951
Product delivery mechanism issue 51.30 17.13 13 14813 305 50589993
Glaucoma 51.19 17.13 40 14786 15646 50574652
Iris disorder 51.10 17.13 10 14816 66 50590232
Hordeolum 48.06 17.13 20 14806 2333 50587965
Eyelash changes 46.79 17.13 7 14819 4 50590294
Cataract 46.34 17.13 63 14763 47237 50543061
Expired product administered 45.68 17.13 25 14801 5357 50584941
Dark circles under eyes 44.79 17.13 13 14813 514 50589784
Eye infection 44.41 17.13 30 14796 9376 50580922
Product packaging quantity issue 43.21 17.13 15 14811 1065 50589233
Product quality issue 42.91 17.13 49 14777 30809 50559489
Visual impairment 42.91 17.13 74 14752 68201 50522097
Eye inflammation 42.65 17.13 22 14804 4186 50586112
Corneal oedema 39.54 17.13 15 14811 1372 50588926
Body height decreased 38.72 17.13 27 14799 8881 50581417
Joint swelling 38.51 17.13 12 14814 245274 50345024
Lid sulcus deepened 38.21 17.13 8 14818 77 50590221
Conjunctival hyperaemia 36.89 17.13 16 14810 2066 50588232
Eyelid sensory disorder 36.06 17.13 7 14819 44 50590254
Eyelash hyperpigmentation 35.68 17.13 5 14821 0 50590298
Periorbital fat atrophy 35.68 17.13 5 14821 0 50590298
Maternal exposure during pregnancy 35.63 17.13 3 14823 159775 50430523
Product container issue 35.53 17.13 14 14812 1418 50588880
Trichiasis 34.26 17.13 7 14819 59 50590239
Conjunctivitis 33.93 17.13 32 14794 16113 50574185
Pyrexia 33.80 17.13 37 14789 380166 50210132
Eye disorder 33.51 17.13 34 14792 18705 50571593
Eye allergy 32.70 17.13 11 14815 710 50589588
Toxicity to various agents 32.28 17.13 11 14815 212488 50377810
Application site discolouration 32.27 17.13 11 14815 739 50589559
Scleral discolouration 31.08 17.13 9 14817 353 50589945
Application site pain 30.47 17.13 17 14809 3781 50586517
Application site pruritus 27.93 17.13 16 14810 3743 50586555
Asthenopia 27.90 17.13 13 14813 1984 50588314
Nausea 26.98 17.13 111 14715 705287 49885011
Therapeutic product effect decreased 26.71 17.13 4 14822 136046 50454252
Pain 26.13 17.13 85 14741 578818 50011480
Corneal opacity 25.84 17.13 9 14817 645 50589653
Systemic lupus erythematosus 25.70 17.13 5 14821 140617 50449681
Condition aggravated 25.19 17.13 30 14796 297028 50293270
Application site erythema 25.14 17.13 16 14810 4522 50585776
Intraocular pressure decreased 25.13 17.13 6 14820 109 50590189
Milia 24.93 17.13 5 14821 38 50590260
Photophobia 24.80 17.13 26 14800 14861 50575437
Accidental exposure to product 24.55 17.13 32 14794 23025 50567273
Application site irritation 24.09 17.13 11 14815 1604 50588694
Glossodynia 23.62 17.13 3 14823 115566 50474732
Punctate keratitis 23.30 17.13 8 14818 549 50589749
Exposure during pregnancy 22.76 17.13 4 14822 121011 50469287
Cystoid macular oedema 22.36 17.13 10 14816 1389 50588909
Eyelid vascular disorder 21.41 17.13 3 14823 0 50590298
Prostaglandin analogue periorbitopathy 21.41 17.13 3 14823 0 50590298
Arthralgia 20.75 17.13 63 14763 438639 50151659
Infusion related reaction 20.68 17.13 12 14814 169545 50420753
Periorbital disorder 20.63 17.13 4 14822 25 50590273
Product physical consistency issue 20.61 17.13 7 14819 465 50589833
Contraindicated product administered 20.47 17.13 9 14817 148949 50441349
Thrombocytopenia 20.46 17.13 6 14820 127667 50462631
Product container seal issue 19.86 17.13 5 14821 114 50590184
Drug intolerance 19.79 17.13 21 14805 219083 50371215
Alopecia 19.46 17.13 26 14800 245021 50345277
Visual field defect 19.42 17.13 15 14811 5764 50584534
Overdose 19.41 17.13 3 14823 99724 50490574
Drug interaction 19.33 17.13 18 14808 199603 50390695
Meibomianitis 19.25 17.13 4 14822 37 50590261
Intraocular pressure test abnormal 19.02 17.13 5 14821 136 50590162
Therapeutic response decreased 18.50 17.13 42 14784 47189 50543109
Product odour abnormal 18.18 17.13 8 14818 1069 50589229
Enophthalmos 18.15 17.13 4 14822 50 50590248
Seizure 18.06 17.13 6 14820 117868 50472430
Blepharospasm 17.86 17.13 11 14815 2937 50587361
Flat anterior chamber of eye 17.73 17.13 4 14822 56 50590242
Ulcerative keratitis 17.52 17.13 10 14816 2323 50587975
General physical health deterioration 17.48 17.13 10 14816 142424 50447874
Therapeutic product effect incomplete 17.26 17.13 3 14823 91512 50498786
Eyelash thickening 17.25 17.13 3 14823 9 50590289
Reaction to preservatives 17.22 17.13 5 14821 198 50590100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Treatment failure 559.80 17.62 220 5128 36719 29532460
Intraocular pressure increased 320.25 17.62 88 5260 4701 29564478
Eye irritation 175.14 17.62 58 5290 5840 29563339
Ocular hyperaemia 150.39 17.62 58 5290 9069 29560110
Eye pain 95.25 17.62 45 5303 11550 29557629
Visual acuity reduced 90.32 17.62 47 5301 14829 29554350
Growth of eyelashes 57.18 17.62 10 5338 57 29569122
Vision blurred 55.83 17.62 51 5297 40125 29529054
Conjunctival hyperaemia 55.36 17.62 19 5329 2126 29567053
Enophthalmos 54.03 17.62 8 5340 11 29569168
Corneal endothelial cell loss 53.33 17.62 7 5341 0 29569179
Eye pruritus 48.88 17.62 21 5327 4311 29564868
Choroidal detachment 45.29 17.62 11 5337 356 29568823
Glaucoma 42.83 17.62 21 5327 5836 29563343
Corneal oedema 41.07 17.62 13 5335 1129 29568050
Cataract 40.38 17.62 33 5315 22345 29546834
Erythema of eyelid 38.60 17.62 11 5337 667 29568512
Blepharal pigmentation 38.09 17.62 5 5343 0 29569179
Scleral hyperaemia 37.13 17.62 7 5341 64 29569115
Visual field defect 36.95 17.62 17 5331 4099 29565080
Corneal opacity 36.91 17.62 10 5338 503 29568676
Fat tissue decreased 36.74 17.62 7 5341 68 29569111
Lacrimation increased 33.81 17.62 19 5329 6961 29562218
Foreign body sensation in eyes 31.61 17.62 9 5339 544 29568635
Punctate keratitis 31.02 17.62 8 5340 332 29568847
Eyelid irritation 30.98 17.62 6 5342 64 29569115
Instillation site pain 29.16 17.62 6 5342 89 29569090
Cardioactive drug level increased 28.97 17.62 11 5337 1642 29567537
Corneal neovascularisation 27.34 17.62 5 5343 38 29569141
Keratitis interstitial 25.47 17.62 4 5344 10 29569169
Lid sulcus deepened 25.20 17.62 5 5343 61 29569118
Intraocular pressure fluctuation 24.46 17.62 4 5344 14 29569165
Blindness 24.39 17.62 19 5329 12004 29557175
Corneal erosion 23.39 17.62 5 5343 90 29569089
Corneal pigmentation 22.86 17.62 3 5345 0 29569179
Blepharitis 22.20 17.62 8 5340 1032 29568147
Macular oedema 21.59 17.62 10 5338 2448 29566731
Corneal infiltrates 21.21 17.62 5 5343 142 29569037
Product packaging quantity issue 20.61 17.62 7 5341 758 29568421
Eye swelling 20.48 17.62 15 5333 8642 29560537
Visual acuity tests abnormal 20.07 17.62 4 5344 50 29569129
Aortic stenosis 19.95 17.62 11 5337 3883 29565296
Eye disorder 19.50 17.62 14 5334 7820 29561359
Intraocular pressure decreased 19.21 17.62 4 5344 63 29569116
Blood pressure systolic increased 18.85 17.62 19 5329 16826 29552353
Computerised tomogram head abnormal 18.26 17.62 4 5344 81 29569098
Skin hypopigmentation 18.25 17.62 5 5343 262 29568917
Product container issue 18.22 17.62 6 5342 591 29568588
Dry eye 18.07 17.62 13 5335 7283 29561896
Uveitis 18.03 17.62 12 5336 5935 29563244
Abnormal sensation in eye 17.74 17.62 6 5342 642 29568537

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ocular hyperaemia 1189.07 15.04 357 13427 22207 64462741
Eye irritation 1087.76 15.04 308 13476 15548 64469400
Erythema of eyelid 1028.58 15.04 199 13585 1769 64483179
Madarosis 747.69 15.04 157 13627 2173 64482775
Eye pruritus 738.85 15.04 217 13567 12442 64472506
Eyelids pruritus 648.02 15.04 113 13671 519 64484429
Eyelid irritation 453.63 15.04 75 13709 231 64484717
Intraocular pressure increased 383.76 15.04 119 13665 8183 64476765
Eyelid oedema 368.88 15.04 127 13657 12152 64472796
Eye swelling 305.23 15.04 130 13654 22151 64462797
Eye pain 238.21 15.04 122 13662 31503 64453445
Blepharal pigmentation 200.32 15.04 29 13755 21 64484927
Vision blurred 163.24 15.04 143 13641 90173 64394775
Growth of eyelashes 142.73 15.04 25 13759 118 64484830
Lacrimation increased 141.64 15.04 72 13712 18274 64466674
Dry eye 133.55 15.04 81 13703 28938 64456010
Trichorrhexis 128.37 15.04 30 13754 690 64484258
Visual acuity reduced 128.10 15.04 77 13707 27064 64457884
Skin hyperpigmentation 123.15 15.04 48 13736 6503 64478445
Eye discharge 116.32 15.04 43 13741 5041 64479907
Blepharitis 111.20 15.04 35 13749 2520 64482428
Scleral hyperaemia 107.88 15.04 22 13762 260 64484688
Eyelid exfoliation 93.06 15.04 17 13767 106 64484842
Eyelid pain 90.59 15.04 19 13765 260 64484688
Iris hyperpigmentation 77.85 15.04 11 13773 5 64484943
Conjunctival hyperaemia 74.80 15.04 29 13755 3870 64481078
Foreign body sensation in eyes 72.14 15.04 23 13761 1726 64483222
Inappropriate schedule of product administration 69.60 15.04 92 13692 92194 64392754
Eyelash discolouration 69.34 15.04 12 13772 52 64484896
Abnormal sensation in eye 68.32 15.04 22 13762 1705 64483243
Product administered at inappropriate site 66.37 15.04 25 13759 3085 64481863
Wrong technique in product usage process 63.84 15.04 74 13710 64900 64420048
Glaucoma 63.51 15.04 41 13743 16307 64468641
Body height decreased 62.25 15.04 31 13753 7523 64477425
Enophthalmos 61.01 15.04 11 13773 63 64484885
Cataract 60.02 15.04 64 13720 51198 64433750
Erythema 55.46 15.04 123 13661 186947 64298001
Eyelid thickening 49.01 15.04 9 13775 58 64484890
Visual field defect 48.78 15.04 27 13757 8119 64476829
Fat tissue decreased 46.26 15.04 9 13775 82 64484866
Choroidal detachment 43.81 15.04 12 13772 530 64484418
Corneal oedema 43.43 15.04 17 13767 2326 64482622
Hair growth abnormal 39.88 15.04 16 13768 2336 64482612
Eyelid disorder 39.85 15.04 14 13770 1417 64483531
Drug ineffective 38.91 15.04 309 13475 839938 63645010
Punctate keratitis 38.27 15.04 12 13772 853 64484095
Toxicity to various agents 36.54 15.04 16 13768 363497 64121451
Eyelid margin crusting 36.15 15.04 11 13773 707 64484241
Lid sulcus deepened 35.88 15.04 8 13776 148 64484800
Ocular discomfort 34.70 15.04 17 13767 3982 64480966
Blindness 34.08 15.04 32 13752 21987 64462961
Eye colour change 33.55 15.04 9 13775 367 64484581
Corneal endothelial cell loss 33.32 15.04 5 13779 6 64484942
Skin irritation 33.12 15.04 22 13762 9172 64475776
Periorbital disorder 32.12 15.04 6 13778 43 64484905
Eye inflammation 31.58 15.04 17 13767 4840 64480108
Swelling of eyelid 30.68 15.04 13 13771 2179 64482769
Eye infection 30.55 15.04 21 13763 9260 64475688
Skin discolouration 29.45 15.04 37 13747 35218 64449730
Ulcerative keratitis 29.39 15.04 14 13770 3083 64481865
Macular oedema 28.78 15.04 16 13768 4851 64480097
Instillation site pain 28.30 15.04 9 13775 670 64484278
Eyelid rash 28.03 15.04 6 13778 91 64484857
Eyelid sensory disorder 27.68 15.04 5 13779 29 64484919
Eyelash thickening 27.57 15.04 4 13780 3 64484945
Conjunctivitis 26.66 15.04 27 13757 20327 64464621
Intraocular pressure fluctuation 26.06 15.04 5 13779 42 64484906
Corneal erosion 25.85 15.04 7 13777 296 64484652
Visual impairment 25.72 15.04 52 13732 74025 64410923
Product container issue 25.51 15.04 9 13775 922 64484026
Flat anterior chamber of eye 25.08 15.04 6 13778 153 64484795
Application site discolouration 23.77 15.04 8 13776 712 64484236
Trichiasis 23.41 15.04 5 13779 75 64484873
Expired product administered 23.21 15.04 15 13769 5972 64478976
Eyelid skin dryness 22.71 15.04 5 13779 87 64484861
Ocular surface disease 22.55 15.04 5 13779 90 64484858
Periorbital fat atrophy 22.35 15.04 3 13781 0 64484948
Eyelash hyperpigmentation 22.35 15.04 3 13781 0 64484948
Corneal infiltrates 21.60 15.04 6 13778 279 64484669
Visual acuity tests abnormal 21.31 15.04 5 13779 117 64484831
Iris disorder 20.54 15.04 6 13778 335 64484613
Intraocular pressure decreased 19.72 15.04 5 13779 163 64484785
Cardioactive drug level increased 19.43 15.04 11 13773 3454 64481494
Angle closure glaucoma 19.26 15.04 10 13774 2647 64482301
Corneal disorder 18.74 15.04 9 13775 2018 64482930
Eye haemorrhage 18.71 15.04 15 13769 8345 64476603
Asthenopia 18.66 15.04 9 13775 2038 64482910
Meibomianitis 18.49 15.04 4 13780 64 64484884
Corneal opacity 18.32 15.04 7 13777 898 64484050
Prostaglandin analogue periorbitopathy 17.53 15.04 3 13781 12 64484936
Photophobia 17.48 15.04 20 13764 17273 64467675
Extrasystoles 17.19 15.04 13 13771 6645 64478303
Choroidal effusion 17.09 15.04 6 13778 606 64484342
Blepharospasm 17.02 15.04 10 13774 3365 64481583
Blindness unilateral 17.01 15.04 13 13771 6748 64478200
Eyelid ptosis 17.00 15.04 15 13769 9510 64475438
Incorrect dose administered 16.90 15.04 39 13745 60726 64424222
Fall 16.86 15.04 149 13635 416677 64068271
Keratitis interstitial 16.82 15.04 3 13781 16 64484932
Computerised tomogram head abnormal 16.61 15.04 4 13780 105 64484843
Application site pruritus 16.58 15.04 10 13774 3529 64481419
Arcus lipoides 16.52 15.04 3 13781 18 64484930
Pyrexia 16.23 15.04 63 13721 558581 63926367
Macular fibrosis 16.18 15.04 6 13778 708 64484240
Instillation site reaction 16.13 15.04 5 13779 342 64484606
Eye disorder 16.07 15.04 20 13764 18849 64466099
Superficial injury of eye 15.94 15.04 4 13780 125 64484823
Intraocular pressure test abnormal 15.79 15.04 4 13780 130 64484818
Thrombocytopenia 15.47 15.04 15 13769 223786 64261162
Reaction to preservatives 15.39 15.04 4 13780 144 64484804
Corneal neovascularisation 15.31 15.04 4 13780 147 64484801
Condition aggravated 15.10 15.04 36 13748 372390 64112558
Uveitis 15.10 15.04 16 13768 12692 64472256

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC S01EE03 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Prostaglandin analogues
FDA CS M0017805 Prostaglandins
FDA EPC N0000175454 Prostaglandin Analog
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:39456 antiglaucoma agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ocular hypertension indication 4210003 DOID:9282
Hypertrichosis of eyelid indication 79830009 DOID:11669
Open-angle glaucoma indication 84494001 DOID:1067
Aphakia contraindication 24010005
Macular retinal edema contraindication 37231002 DOID:4449
Iritis contraindication 65074000 DOID:1406
Pseudophakia contraindication 95217000
Uveitis contraindication 128473001 DOID:13141
Liver function tests abnormal contraindication 166603001
Cystoid macular edema contraindication 193387007 DOID:4447
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.89 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8263054 Jan. 15, 2023 METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8632760 Jan. 15, 2023 METHOD OF INCREASING EYELASH GROWTH
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8758733 Jan. 15, 2023 METHOD OF INCREASING EYELASH GROWTH
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8986715 Jan. 15, 2023 METHOD OF INCREASING HAIR GROWTH
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 9216183 Jan. 15, 2023 METHOD OF INCREASING EYELASH GROWTH
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 9226931 Jan. 15, 2023 METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8038988 Aug. 25, 2023 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
10MCG DURYSTA ALLERGAN INC N211911 March 4, 2020 RX IMPLANT OPHTHALMIC 10398707 April 30, 2024 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8101161 May 25, 2024 METHOD OF INCREASING HAIR GROWTH
0.03% LATISSE ALLERGAN N022369 Dec. 24, 2008 RX SOLUTION/DROPS TOPICAL 8101161 May 25, 2024 METHOD OF STIMULATING HAIR GROWTH
10MCG DURYSTA ALLERGAN INC N211911 March 4, 2020 RX IMPLANT OPHTHALMIC 8673341 Feb. 19, 2025 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8299118 March 16, 2025 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8309605 March 16, 2025 A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8309605 March 16, 2025 METHOD OF TREATING GLAUCOMA IN A PATIENT
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8338479 March 16, 2025 A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8524777 March 16, 2025 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8586630 March 16, 2025 A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 8772338 March 16, 2025 A METHOD OF LOWERING INTRAOCULAR PRESSURE
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 9155716 March 16, 2025 A METHOD OF LOWERING INTRAOCULAR PRESSURE
0.01% LUMIGAN ALLERGAN N022184 Aug. 31, 2010 RX SOLUTION/DROPS OPHTHALMIC 9241918 March 16, 2025 METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
10MCG DURYSTA ALLERGAN INC N211911 March 4, 2020 RX IMPLANT OPHTHALMIC 8206737 April 7, 2027 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT
10MCG DURYSTA ALLERGAN INC N211911 March 4, 2020 RX IMPLANT OPHTHALMIC 9980974 Oct. 31, 2034 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MCG DURYSTA ALLERGAN INC N211911 March 4, 2020 RX IMPLANT OPHTHALMIC March 4, 2023 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin F2-alpha receptor GPCR AGONIST Ki 5.30 WOMBAT-PK CHEMBL
Aldo-keto reductase family 1 member C3 Enzyme IC50 5.30 CHEMBL

External reference:

IDSource
D02724 KEGG_DRUG
283810 RXNORM
C0937917 UMLSCUI
CHEBI:51230 CHEBI
15M PDB_CHEM_ID
CHEMBL1200963 ChEMBL_ID
D000069580 MESH_DESCRIPTOR_UI
DB00905 DRUGBANK_ID
5311027 PUBCHEM_CID
1958 IUPHAR_LIGAND_ID
8035 INN_ID
QXS94885MZ UNII
15937 MMSL
234008 MMSL
41256 MMSL
009115 NDDF
129492005 SNOMEDCT_US
395300006 SNOMEDCT_US
4021262 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 0023-3205 SOLUTION/ DROPS 0.10 mg OPHTHALMIC NDA 25 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 0023-3205 SOLUTION/ DROPS 0.10 mg OPHTHALMIC NDA 25 sections
LATISSE HUMAN PRESCRIPTION DRUG LABEL 1 0023-3616 SOLUTION/ DROPS 0.30 mg OPHTHALMIC NDA 25 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 0023-9187 SOLUTION/ DROPS 0.30 mg OPHTHALMIC Export only 1 sections
DURYSTA HUMAN PRESCRIPTION DRUG LABEL 1 0023-9652 IMPLANT 10 ug INTRACAMERAL NDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 0781-6206 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
BIMATOPROST HUMAN PRESCRIPTION DRUG LABEL 1 42571-128 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
BIMATOPROST HUMAN PRESCRIPTION DRUG LABEL 1 42571-128 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 50383-908 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 50383-908 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 50383-912 SOLUTION 3 ug TOPICAL ANDA 22 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 50383-912 SOLUTION 3 ug TOPICAL ANDA 22 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 54868-4575 SOLUTION/ DROPS 0.30 mg OPHTHALMIC NDA 25 sections
LUMIGAN HUMAN PRESCRIPTION DRUG LABEL 1 54868-6304 SOLUTION/ DROPS 0.10 mg OPHTHALMIC NDA 25 sections
bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 57297-429 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 60505-0583 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 60505-0583 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 24 sections
Bimatoprost Human Prescription Drug Label 1 62332-507 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 62332-507 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
bimatoprost Human Prescription Drug Label 1 62332-511 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 22 sections
Bimatoprost Human Prescription Drug Label 1 68083-295 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-295 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-296 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-296 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-439 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost Human Prescription Drug Label 1 68083-439 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 68180-429 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 21 sections
bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 68180-429 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 21 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-401 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections
Bimatoprost HUMAN PRESCRIPTION DRUG LABEL 1 70069-401 SOLUTION/ DROPS 0.30 mg OPHTHALMIC ANDA 23 sections